作者
Nuno Sousa, Catia Faustino, Lucia Maria Nunes Aguas, João Freire, Camila Coutinho, Ilda Faustino, Andreia Capela, Telma Costa, Andreia Sofia Alves Costa, Sara Coelho, Filipa Pereira, Sofia Coelho Abreu, Ana Sofia Rolo, Andre Albergaria, Jorge Lima, Xiaogang Wen, Carina Mesquita, Claudia Camila Dias, Luis Filipe Azevedo, Fatima Carneiro
发表日期
2019/5/20
来源
Journal of Clinical Oncology
卷号
37
期号
15_suppl
页码范围
4040-4040
出版商
American Society of Clinical Oncology
简介
4040
Background: Gastric cancer is the 5th cancer diagnosis and 3rd cause of cancer death worldwide. Metastatic gastric cancer (mGC) has a median survival of 11 months. mGC is an heterogeneous disease and different biologic characteristics may justify differential therapeutic opportunities. Tumors with homologous recombination (HR) deficiency may benefit with treatment with PARP inhibitors or immune checkpoint inhibitors. The purpose of this study was to evaluate the prevalence and prognostic impact of altered expression of HR proteins as surrogates for homologous recombination deficiency (HRD) in mGC. Methods: Multicenter retrospective cohort of mGC treated with platinum-based chemotherapy. HRD defined as absence of at least one of the following proteins: ATM, ATR, CHK2, RAD51, RAD52, BRCA1, BRCA2, MRE11 by immunohistochemistry. Survival time calculated as the difference between first …
学术搜索中的文章
N Sousa, C Faustino, LMN Aguas, J Freire, C Coutinho… - 2019